Necitumumab (anti-EGFR)

Catalog No.A2048 Purity:98%

Necitumumab (anti-EGFR) is an epidermal growth factor receptor (EGFR) antagonist that can be used in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Click to purchase the isotype control of Necitumumab (anti-EGFR)

Purity & Quality Control

Batch: A204801 Purity: 98% Protein concentration: 4.6mg/ml Endotoxin Level: <1 EU/mg

Choose Selective EGFR Inhibitors

Name	Citation	EGFR/ErbB1	HER2/ErbB2	ErbB3	ErbB4	mutant EGFR	Others
Saracatinib (AZD0530)	291	+++					c-Src,c-YES,LCK
Canertinib (CI-1033)	48	++++	+++
AG-490	129	+					JAK2 (V617F)
CP-724714	108		++
WZ4002	34	++++
Sapitinib (AZD8931)	46	+++	+++	+++
CUDC-101	22	+++	++				HDAC,HDAC1,HDAC6
AG-1478	96	+++
PD153035 HCl	17	++++
Pelitinib (EKB-569)	11	+	+				Src,MEK/ERK,Raf
AEE788 (NVP-AEE788)	13	++++	+++		+		c-Abl,FLT1,c-Fms
AC480 (BMS-599626)	10	++	++		+
AP26113-analog (ALK-IN-1)	4					++	ALK,IGF1R,INSR
WZ3146	2	++++
Allitinib tosylate	16	++++	+++		++++
Rociletinib (CO-1686)	36	++
Varlitinib	8	+++	++++
Icotinib (BPI-2009H)	9	+++
TAK-285	4	++	++		+		MEK1,Aurora B,LCK
WHI-P154	11	+++					Src,VEGFR,JAK3
Daphnetin	4	+					PKA,PKC
PD168393	6	++++
CNX-2006	2	++				++
Tyrphostin 9	1	+					PDGFR
AG-18	1	+
Icotinib Hydrochloride	0	+++
HS-10296 hydrochloride	0					++++
MTX-531	0	++					PI3Kα
Avitinib maleate	0	+++				++++	BTK
limertinib	0					++++
AG 825	0		+				PDGFR
4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine	0	+
AST-1306	0	++++	+++		++++
ErbB2 inhibitor	0		+		+
Tuxobertinib (BDTX-189)	2	++++	++++				RIPK2,BLK
Epertinib hydrochloride	0	++++	+++		+++
JND3229	0	+++				++	EGFR C797S
BI-4020	1					++++
Tyrphostin AG-528	0	+	+
AG 556	0	+
Canertinib dihydrochloride	8	+++	+++
EGFR Inhibitor	3	++					Microtubules
SU5214	0	+					VEGFR2
RG 13022	0	+
TQB3804	0					++++
zipalertinib (TAS6417)	3	+++			+++	++++	TXK,BMX
Pyrotinib dimaleate	4	++	++
PD153035	14	++++
AG 494	0	+
AG 555	0	+
Theliatinib (HMPL-309)	0	+++				++
Avitinib (Abivertinib)	2					++++	JAK3,BTK
Lazertinib	6	++++				++++	Del19,L85R
Lifirafenib (BGB-283)	6	++				+	WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)
Nazartinib (EGF816)	6	++				++
Zorifertinib (AZD3759)	6	++++
CL-387785 (EKI-785)	4	++++
Poziotinib	34	+++	+++		++
AZ5104	4	++++			+++		ACK1,BLK,BRK
AV-412 free base	0	++++	++			++++
HER2-Inhibitor-1		✔
WZ8040	✔
Genistein	✔					topo II
Rezivertinib	✔
BDTX-1535	✔
Falnidamol	✔
BLU-945	✔
Sunvozertinib (DZD9008)	✔
CH7233163	✔
Licochalcone D	✔					NF-κB,PARP,Caspase
Alflutinib (Furmonertinib) mesylate	✔					CYP3A4
(Rac)-JBJ-04-125-02	✔
Tyrphostin AG30 (AG30)	✔
AG-1557	✔
AG99	✔
MTX-211	✔					PI3K
RG14620	✔					ABCG2
Almonertinib (HS-10296)					✔
Cyasterone	✔
Norcantharidin	✔					c-Met
Naquotinib(ASP8273)	✔
EAI045					✔
Olmutinib (BI 1482694)	✔					BTK
Butein	✔
Chrysophanic Acid	✔					mTOR
EGCG ((-)-Epigallocatechin Gallate)	✔					DNMT,telomerase,FASN

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Necitumumab (anti-EGFR) is an epidermal growth factor receptor (EGFR) antagonist that can be used in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous non-small cell lung cancer.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	906805-06-9
Molecular Weight	150 kDa
Isotype	human IGg1, κ
Application	Necitumumab (anti-EGFR)
Source	CHO
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.